Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.02 ^USD	+2.87%		+0.20%	+15.94%

Mar. 20	Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	MT
Mar. 20	Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	CI

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

February 29, 2024 at 04:16 pm EST

Puma Biotechnology, Inc. provided earnings guidance for the first quarter and full year of 2024. For the quarter, the company expects Net loss to be $10 million - $12 million.

For the year, the company expects Net Income to be $12 million - $15 million.

Latest news about Puma Biotechnology, Inc.

Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	Mar. 20	MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Mar. 20	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : Puma Biotechnology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 29	CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	Feb. 29	MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	Feb. 13	CI
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Dec. 11	CI
Transcript : Puma Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.17, vs. Street Est of $0.14	Nov. 02	MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023	Nov. 02	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting	23-10-14	CI
North American Morning Briefing : Stock Futures Edge Higher as PMI Data Awaited	23-09-22	DJ
Puma Biotechnology Gets FDA Orphan Drug Designation For Alisertib	23-09-21	MT
Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation	23-09-21	DJ
Puma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer Drug	23-09-21	DJ
FDA Clears Puma Biotechnology to Begin Mid-Stage Trial in Small Cell Lung Cancer	23-08-08	MT
Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer	23-08-08	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Transcript : Puma Biotechnology, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q2 EPS $0.10, vs. Street Est of $0.07	23-08-03	MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023	23-08-03	CI
Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting	23-06-04	CI

Chart Puma Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Puma Biotechnology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.02 USD

Average target price

4.333 USD

Spread / Average Target

-13.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PUMA BIOTECHNOLOGY, INC.	+15.94%	242M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research